The Scientist

» industry and cell & molecular biology

Most Recent

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

1 Comment

image: Thermo Fisher to Acquire FEI

Thermo Fisher to Acquire FEI

By | June 1, 2016

In a $4.2 billion deal, the science equipment giant is buying the Hillsboro, Oregon-based electron microscope maker.

0 Comments

image: Do Patents Promote or Stall Innovation?

Do Patents Promote or Stall Innovation?

By | June 1, 2016

A petition recently filed with the Supreme Court triggers renewed debate about the role of patents in the diagnostics sector.

3 Comments

image: Generating Cardiac Precursor Cells

Generating Cardiac Precursor Cells

By | June 1, 2016

Researchers derive cardiac precursors to form cardiac muscle, endothelial, and smooth muscle cells in mice.

0 Comments

image: The Fatty Acid–Ketone Switch

The Fatty Acid–Ketone Switch

By | June 1, 2016

In failing hearts, cardiomyocytes change their fuel preference.

1 Comment

image: In Failing Hearts, Cardiomyocytes Alter Metabolism

In Failing Hearts, Cardiomyocytes Alter Metabolism

By | June 1, 2016

While the heart cells normally burn fatty acids, when things go wrong ketones become the preferred fuel source.

0 Comments

image: Editing Genomes to Record Cellular Histories

Editing Genomes to Record Cellular Histories

By | May 26, 2016

Researchers harness the power of genome editing to track cell lineages throughout zebrafish development.

0 Comments

image: E.U. Delays Vote on Roundup

E.U. Delays Vote on Roundup

By | May 24, 2016

Newly published research on the key ingredient in the Monsanto-made weed killer is holding up lawmakers’ decisions on whether to continue to allow its sale in Europe.

4 Comments

The US Department of Agriculture orders Santa Cruz Biotechnology to pay a $3.5 million fine and to cease selling research antibodies.

0 Comments

image: Pfizer Scoops Anacor for $5.3 Billion

Pfizer Scoops Anacor for $5.3 Billion

By | May 17, 2016

The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.

0 Comments

Popular Now

  1. Opinion: Why I Published in a Predatory Journal
    News & Opinion Opinion: Why I Published in a Predatory Journal

    My “colleagues” and I at the fictitious Arthur Vandelay Urological Research Institute were surprised to find our bogus “uromycitisis” case report swiftly accepted, with only minor revisions requested.

  2. Consilience, Episode 3: Cancer, Obscured
  3. March for Science: Dispatches from Washington, DC
  4. Record-Setting Corn Grows 45 Feet Tall
AAAS